PARIS - june 11, 2009 - Biosystems International (BSI) a biotechnology company focused on the development of novel monoclonal antibody-based diagnostics for cancer and metabolic diseases has established a licensing agreement with the Lohocla Research Corporation for the use of BSI’s patented monoclonal antibody proteomics platform for the discovery of novel alcoholism liver disease biomarkers in blood. Terms of the agreement were not disclosed...About Biosystems International
Biosystems International (BSI) is a biotechnology company aiming to become a world leader in the discovery and development of novel diagnostics for diseases with critical unmet needs. Using our proprietary monoclonal antibody proteomics process BSI rapidly discovers novel biomarkers and corresponding antibodies in a single step. The company is currently focused on the discovery and development of diagnostic tests in the areas of cancer and metabolic diseases as well as the
development and commercialization of antibody arrays for plasma proteome profiling... [PDF] Biosystems International's Press Release -
